Table of Contents

1 Study Coverage

• 1.1 Gastrointestinal Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Gastrointestinal Drugs Market Size Growth Rate by Product
  • 1.4.2 Prescription Gastrointestinal Drug
  • 1.4.3 OTC Gastrointestinal Drug
• 1.5 Market by End User
  • 1.5.1 Global Gastrointestinal Drugs Market Size Growth Rate by End User
  • 1.5.2 Chronic Gastritis
  • 1.5.3 Functional Dyspepsia
  • 1.5.4 Peptic Ulcer
  • 1.5.5 Acute Gastroenteritis
  • 1.5.6 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Gastrointestinal Drugs Market Size
  • 2.1.1 Global Gastrointestinal Drugs Revenue 2014-2025
  • 2.1.2 Global Gastrointestinal Drugs Sales 2014-2025
• 2.2 Gastrointestinal Drugs Growth Rate by Regions
  • 2.2.1 Global Gastrointestinal Drugs Sales by Regions
  • 2.2.2 Global Gastrointestinal Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Gastrointestinal Drugs Sales by Manufacturers
  • 3.1.1 Gastrointestinal Drugs Sales by Manufacturers
  • 3.1.2 Gastrointestinal Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Gastrointestinal Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Gastrointestinal Drugs Revenue by Manufacturers
  • 3.2.1 Gastrointestinal Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Gastrointestinal Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Gastrointestinal Drugs Price by Manufacturers
• 3.4 Gastrointestinal Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Gastrointestinal Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Gastrointestinal Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Gastrointestinal Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Gastrointestinal Drugs Sales by Product
• 4.2 Global Gastrointestinal Drugs Revenue by Product
• 4.3 Gastrointestinal Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Gastrointestinal Drugs Breakdown Data by End User

6 North America

• 6.1 North America Gastrointestinal Drugs by Countries
  • 6.1.1 North America Gastrointestinal Drugs Sales by Countries
  • 6.1.2 North America Gastrointestinal Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Gastrointestinal Drugs by Product
• 6.3 North America Gastrointestinal Drugs by End User

7 Europe

• 7.1 Europe Gastrointestinal Drugs by Countries
  • 7.1.1 Europe Gastrointestinal Drugs Sales by Countries
  • 7.1.2 Europe Gastrointestinal Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Gastrointestinal Drugs by Product
• 7.3 Europe Gastrointestinal Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Gastrointestinal Drugs by Countries
  • 8.1.1 Asia Pacific Gastrointestinal Drugs Sales by Countries
  • 8.1.2 Asia Pacific Gastrointestinal Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Gastrointestinal Drugs by Product
• 8.3 Asia Pacific Gastrointestinal Drugs by End User

9 Central & South America

• 9.1 Central & South America Gastrointestinal Drugs by Countries
  • 9.1.1 Central & South America Gastrointestinal Drugs Sales by Countries
  • 9.1.2 Central & South America Gastrointestinal Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Gastrointestinal Drugs by Product
• 9.3 Central & South America Gastrointestinal Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Gastrointestinal Drugs by Countries
  • 10.1.1 Middle East and Africa Gastrointestinal Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Gastrointestinal Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Gastrointestinal Drugs by Product
• 10.3 Middle East and Africa Gastrointestinal Drugs by End User

11 Company Profiles

• 11.1 AstraZeneca
  • 11.1.1 AstraZeneca Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 AstraZeneca Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 AstraZeneca Gastrointestinal Drugs Products Offered
  • 11.1.5 AstraZeneca Recent Development
• 11.2 Sanofi
  • 11.2.1 Sanofi Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Sanofi Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Sanofi Gastrointestinal Drugs Products Offered
  • 11.2.5 Sanofi Recent Development
• 11.3 Bayer
  • 11.3.1 Bayer Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Bayer Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Bayer Gastrointestinal Drugs Products Offered
  • 11.3.5 Bayer Recent Development
• 11.4 Pfizer
  • 11.4.1 Pfizer Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Pfizer Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Pfizer Gastrointestinal Drugs Products Offered
  • 11.4.5 Pfizer Recent Development
• 11.5 GlaxoSmithKline
  • 11.5.1 GlaxoSmithKline Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 GlaxoSmithKline Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 GlaxoSmithKline Gastrointestinal Drugs Products Offered
  • 11.5.5 GlaxoSmithKline Recent Development
• 11.6 Teva
  • 11.6.1 Teva Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Teva Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Teva Gastrointestinal Drugs Products Offered
  • 11.6.5 Teva Recent Development
• 11.7 Zeria（Tillotts）
  • 11.7.1 Zeria（Tillotts） Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Zeria（Tillotts） Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Zeria（Tillotts） Gastrointestinal Drugs Products Offered
  • 11.7.5 Zeria（Tillotts） Recent Development
• 11.8 Perrigo
  • 11.8.1 Perrigo Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Perrigo Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Perrigo Gastrointestinal Drugs Products Offered
  • 11.8.5 Perrigo Recent Development
• 11.9 Boehringer Ingelheim
  • 11.9.1 Boehringer Ingelheim Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Boehringer Ingelheim Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Boehringer Ingelheim Gastrointestinal Drugs Products Offered
  • 11.9.5 Boehringer Ingelheim Recent Development
• 11.10 Purdue Pharma
  • 11.10.1 Purdue Pharma Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Purdue Pharma Gastrointestinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Purdue Pharma Gastrointestinal Drugs Products Offered
  • 11.10.5 Purdue Pharma Recent Development
• 11.11 C.B. Fleet
• 11.12 Abbott
• 11.13 Jiangzhong
• 11.14 Xian-Janssen

12 Future Forecast

• 12.1 Gastrointestinal Drugs Market Forecast by Regions
  • 12.1.1 Global Gastrointestinal Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Gastrointestinal Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Gastrointestinal Drugs Market Forecast by Product
  • 12.2.1 Global Gastrointestinal Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Gastrointestinal Drugs Revenue Forecast by Product 2019-2025
• 12.3 Gastrointestinal Drugs Market Forecast by End User
• 12.4 North America Gastrointestinal Drugs Forecast
• 12.5 Europe Gastrointestinal Drugs Forecast
• 12.6 Asia Pacific Gastrointestinal Drugs Forecast
• 12.7 Central & South America Gastrointestinal Drugs Forecast
• 12.8 Middle East and Africa Gastrointestinal Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Gastrointestinal Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
The global Gastrointestinal Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Gastrointestinal Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Gastrointestinal Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gastrointestinal Drugs in these regions.
This research report categorizes the global Gastrointestinal Drugs market by top players/brands, region, type and end user. This report also studies the global Gastrointestinal Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AstraZeneca
Sanofi
Bayer
Pfizer
GlaxoSmithKline
Teva
Zeria（Tillotts）
Perrigo
Boehringer Ingelheim
Purdue Pharma
C.B. Fleet
Abbott
Jiangzhong
Xian-Janssen

Market size by Product
Prescription Gastrointestinal Drug
OTC Gastrointestinal Drug
Market size by End User
Chronic Gastritis
Functional Dyspepsia
Peptic Ulcer
Acute Gastroenteritis
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Gastrointestinal Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Gastrointestinal Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Gastrointestinal Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Gastrointestinal Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Gastrointestinal Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Gastrointestinal Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.